Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75096
UPID:
LRP4_HUMAN
Alternative names:
Multiple epidermal growth factor-like domains 7
Alternative UPACC:
O75096; B2RN39; Q4AC85; Q5KTZ5
Background:
Low-density lipoprotein receptor-related protein 4 (LRP4), also known as Multiple epidermal growth factor-like domains 7, plays a pivotal role in bone formation and neuromuscular junction maintenance. It facilitates SOST-mediated inhibition of Wnt signaling and is crucial for digit differentiation and AGRIN-induced MUSK phosphorylation.
Therapeutic significance:
LRP4's involvement in Cenani-Lenz syndactyly syndrome, Sclerosteosis 2, and congenital myasthenic syndrome 17 highlights its potential as a therapeutic target. Understanding LRP4's functions could lead to innovative treatments for these genetic disorders.